New hope for PMR patients: baricitinib may cut steroid use
NCT ID NCT07279688
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tests whether adding baricitinib (a JAK inhibitor pill) to standard steroid treatment helps people with polymyalgia rheumatica (PMR) achieve disease control with fewer steroids. About 140 adults aged 50+ with active PMR will receive baricitinib or placebo plus steroids for 6 months. The goal is to see if baricitinib allows tapering off steroids while keeping the disease inactive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYMYALGIA RHEUMATICA (PMR) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP - Kremlin-Bicêtre
Le Kremlin-Bicêtre, 94270, France
Contact Email: •••••@•••••
-
Besançon-CIC
Besançon, 25000, France
Contact Email: •••••@•••••
-
CARVAJAL ALEGRIA Guillermo
Tours, France
Contact Email: •••••@•••••
-
CHU Reims
Reims, France
Contact Email: •••••@•••••
-
CHU de Bordeaux Pellegrin
Bordeaux, 33076, France
Contact Email: •••••@•••••
-
CHU de Nice
Nice, 06000, France
Contact Email: •••••@•••••
-
CHU de Toulouse
Toulouse, 31059, France
Contact Email: •••••@•••••
-
DIREZ Guillaume
Le Mans, France
Contact Email: •••••@•••••
-
Dr Alain SARAUX
Brest, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
FAUTREL Bruno - AP-HP La Pitié-Salpétrière
Paris, France
Contact Email: •••••@•••••
-
FLIPO René-Marc
Lille, France
Contact Email: •••••@•••••
-
GOTTENBERG Jacques-Eric
Strasbourg, France
Contact Email: •••••@•••••
-
LE HENAFF Catherine
Morlaix, France
Contact Email: •••••@•••••
-
LEGRAND Jean-Louis
Arras, France
Contact Email: •••••@•••••
-
LESKE Charles
Cholet, France
Contact Email: •••••@•••••
-
OTTAVIANI Sébastien - AP-HP Bichat
Paris, France
Contact Email: •••••@•••••
-
PRATI Clément
Besançon, France
Contact Email: •••••@•••••
-
RAMON André
Dijon, France
Contact Email: •••••@•••••
-
RAT Anne-Christine
Caen, France
Contact Email: •••••@•••••
-
TOURNADRE Anne
Clermont-Ferrand, France
Contact Email: •••••@•••••
-
VIDAL François
Aix-en-Provence, France
Contact Email: •••••@•••••
-
WIRTH Théo
Marseille, France
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.